• Explore /
  • Poster
  • / Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).

Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).

Abstract Poster

Authors

Fred Saad

Fred Saad

University of Montréal Hospital Center, CRCHUM, Montréal, QC, Canada

Fred Saad , Eric Winquist , Stacey Hubay , Scott R. Berry , Hazem Assi , Eric Levesque , Nathalie Aucoin , Piotr Czaykowski , Jean-Baptiste Lattouf , Karine Alloul , John Stewart , Srikala S. Sridhar

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT01254279

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 5062^)

DOI

10.1200/jco.2014.32.15_suppl.5062

Abstract #

5062^

Poster Bd #

191

Abstract Disclosures

Similar Posters

Poster

2015 Genitourinary Cancers Symposium

Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).

Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).

First Author: Alice Clement-Zhao

First Author: Cora N. Sternberg

First Author: Amit Bahl

First Author: Miguel Angel Climent Duran